Barriers to the introduction of novel advanced targeted treatments for Australian dermatology patients: Are skin diseases symptomatic of a systemic healthcare problem?-Reference-Cited by-同舟云学术

Barriers to the introduction of novel advanced targeted treatments for Australian dermatology patients: Are skin diseases symptomatic of a systemic healthcare problem?

Published:2024-06-18 Issue:6 Volume:65 Page:
ISSN:0004-8380
Container-title:Australasian Journal of Dermatology
language:en
Short-container-title:Aust J Dermatology

Author:

Mahar Patrick David¹²³,Crothers Anna¹,Foley Peter¹³⁴^ORCID,Thomas Joseph⁵

Affiliation:

1. Skin Health Institute Melbourne Victoria Australia

2. Department of Dermatology The Royal Children's Hospital Melbourne Victoria Australia

3. Faculty of Medicine, Dentistry & Health Sciences The University of Melbourne Melbourne Victoria Australia

4. Department of Dermatology St Vincent's Hospital Melbourne Victoria Australia

5. Centre for Health Economics Research & Evaluation University of Technology Sydney Sydney New South Wales Australia

Abstract

AbstractThe aim of this article is to provide education to clinicians about certain barriers restricting the use of advanced targeted treatments in Australian health care. For illustrative purposes, the article focuses on dermatological conditions, but the content is relevant to all specialties that treat inflammatory and chronic diseases. Barriers to care discussed result in a lower than necessary standard of care for patients in Australia despite important advancements in medicine.

Publisher

Wiley

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/ajd.14333

Reference10 articles.

1. Cumulative life course impairment in psoriasis: patient perception of disease-related impairment throughout the life course

2. Atopic dermatitis in adults: An Australian management consensus

3. Department of Health and Aged Care.Guidelines for deeds of agreement. Australian Government Department of Health and Aged Care.2024[cited 2024 Jan 25]. Available from:https://www.pbs.gov.au/pbs/industry/listing/elements/deeds‐agreement/b‐background

4. The Pharmaceutical Benefits Scheme.Cost recovery fees and charges[cited 2024 Jan 1]. Available from:https://www.pbs.gov.au/info/industry/listing/elements/fees‐and‐charges

5. Updated S2K guidelines on the management of pemphigus vulgaris and foliaceus initiated by the european academy of dermatology and venereology (EADV)